Minerva Neurosciences (NASDAQ:NERV) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.01, Fidelity Earnings reports.
Minerva Neurosciences stock traded up $0.02 during midday trading on Thursday, hitting $5.18. 8,564 shares of the stock were exchanged, compared to its average volume of 373,022. Minerva Neurosciences has a fifty-two week low of $4.01 and a fifty-two week high of $10.79. The stock has a market capitalization of $181.47 million, a price-to-earnings ratio of -4.00 and a beta of 1.50. The stock’s 50-day simple moving average is $5.48 and its 200 day simple moving average is $6.16.
Several equities analysts have issued reports on NERV shares. ValuEngine downgraded shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 30th. William Blair started coverage on shares of Minerva Neurosciences in a report on Wednesday, September 18th. They set an “outperform” rating and a $26.00 price objective on the stock. BidaskClub raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a report on Friday, August 23rd. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Minerva Neurosciences in a report on Tuesday, October 1st. Finally, Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Minerva Neurosciences presently has an average rating of “Buy” and a consensus target price of $17.44.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Read More: How is a Moving Average Calculated?
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.